Detection of extensive drug resistance by the Xpert MTB/XDR assay in multidrug resistant tuberculosis cases at a tertiary care centre in northern India, and therapeutic decision making for the six-month BPaLM regimen
The Xpert MTB/XDR assay has been approved by World Health Organization (WHO) as a reflex test on sputum samples after testing for rifampicin resistance. Recently, the Union Health Ministry of India in September 2024 approved the introduction of the six-month BPaLM regimen under its National TB Elimi...
Saved in:
| Main Authors: | Richa Misra, Parijat Das, Alok Nath, Zafar Neyaz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405579425000117 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse events reported with BPaL and BPaLM regimens in drug-resistant tuberculosis
by: Kannan Sridharan, et al.
Published: (2025-08-01) -
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
by: Denise Rossato Silva, et al.
Published: (2025-01-01) -
Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan
by: M.A. Khan, et al.
Published: (2024-11-01) -
Xpert MTB/XDR Assay for Detection of Resistance to Isoniazid, Fluoroquinolone, Aminoglycoside, and Ethionamide Among Patients with Pulmonary Tuberculosis in Bangladesh
by: S. M. Mazidur Rahman, et al.
Published: (2025-03-01) -
Xpert MTB/XDR implementation in South Africa: cost outcomes of centralised vs. decentralised approaches
by: N. Cassim, et al.
Published: (2024-05-01)